E-LIB Suche - Ergebnisse für: Van der Wielen, Marie

1

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Pr..:

Ison, Michael G ; Papi, Alberto ; Athan, Eugene...
Clinical Infectious Diseases. 78 (2024) 6 - p. 1732-1744 , 2024

2

1936. Efficacy of One Dose of the Respiratory Syncytial Vir..:

Ison, Michael G ; Papi, Alberto ; Langley, Joanne M...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

3

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is ..:

Feldman, Robert G ; Antonelli-Incalzi, Raffaele ; Steenackers, Katie...
Clinical Infectious Diseases. 78 (2023) 1 - p. 202-209 , 2023

Link: https://doi.org/10.1093/..

4

EFICÁCIA DE UMA VACINA DE PROTEÍNA F PRÉ-FUSÃO DO VÍRUS SIN..:

Michelin, Lessandra ; Hulstrom, Veronica ; Papi, Alberto...
The Brazilian Journal of Infectious Diseases. 27 (2023) - p. 103095 , 2023

Link: https://doi.org/10.1016/..

5

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protei..:

Ison, Michael G ; Papi, Alberto ; Langley, Joanne M...
Open Forum Infectious Diseases. 9 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

6

Immunogenicity of chimeric haemagglutinin-based, universal ..:

Bernstein, David I ; Guptill, Jeffrey ; Naficy, Abdollah...
The Lancet Infectious Diseases. 20 (2020) 1 - p. 80-91 , 2020

Link: https://doi.org/10.1016/..

7

Ten-Year Antibody Persistence and Booster Response to MenAC..:

Vesikari, Timo ; Peyrani, Paula ; Webber, Chris...
Human Vaccines & Immunotherapeutics. 16 (2020) 6 - p. 1280-1291 , 2020

Link: https://doi.org/10.1080/..

8

A phase 2b/3b MenACWY-TT study of long-term antibody persis..:

Borja-Tabora, Charissa Fay Corazon ; Peyrani, Paula ; Webber, Chris...
BMC Infectious Diseases. 20 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

9

Long-term antibody persistence after a booster dose of quad..:

Vesikari, Timo ; Forsten, Aino ; Laudat, France...
Vaccine. 38 (2020) 22 - p. 3902-3908 , 2020

Link: https://doi.org/10.1016/..

10

Efficacy and safety of a booster dose of the meningococcal ..:

Quiambao, Beatriz ; Peyrani, Paula ; Li, Ping...
Human Vaccines & Immunotherapeutics. 16 (2020) 6 - p. 1272-1279 , 2020

Link: https://doi.org/10.1080/..

11

2722 B. Efficacy and Safety of a Booster Dose of the MenACW..:

Quiambao, Beatriz ; Peyrani, Paula ; Webber, Chris...
Open Forum Infectious Diseases. 6 (2019) Supplement_2 - p. S960-S961 , 2019

Link: https://doi.org/10.1093/..

12

1478. Efficacy and Safety of a Booster Dose of the MenACWY-..:

Quiambao, Beatriz ; Peyrani, Paula ; Webber, Chris...
Open Forum Infectious Diseases. 6 (2019) Supplement_2 - p. S539-S539 , 2019

Link: https://doi.org/10.1093/..

13

Immunogenicity and safety of MenACWY-TT, a meningococcal co..:

Dbaibo, Ghassan ; Tinoco Favila, Juan Carlos ; Traskine, Magali..
Vaccine. 36 (2018) 28 - p. 4102-4111 , 2018

Link: https://doi.org/10.1016/..

14

Antibody persistence and booster response 68 months after v..:

Knuf, Markus ; Helm, Klaus ; Kolhe, Devayani..
Vaccine. 36 (2018) 23 - p. 3286-3295 , 2018

Link: https://doi.org/10.1016/..

15

Immunogenicity and safety of the quadrivalent meningococcal..:

Klein, Nicola P. ; Habanec, Tomas ; Kosina, Pavel...
Vaccine. 36 (2018) 17 - p. 2356-2363 , 2018

Link: https://doi.org/10.1016/..